Formula Pharmaceuticals, Inc. Establishes Scientific Advisory Board With Leading Experts In Support Of Chimeric Antigen Receptor Immunotherapy Platform Involving Cytokine Induced Killer Cells

BERWYN, Pa.--(BUSINESS WIRE)--Formula Pharmaceuticals, Inc. (“Formula”) today announced the appointment of leading experts to its newly formed scientific advisory board (SAB). The SAB will serve as a strategic resource to Formula as it continues to develop Chimeric Antigen Receptor (CAR) immunotherapies leveraging Cytokine Induced Killer cells targeting cancer and autoimmune disease.

Help employers find you! Check out all the jobs and post your resume.